MMI Receives FDA IDE Approval for First Robotic Microsurgical Study Targeting Alzheimer’s Disease
Medical Microinstruments (MMI) announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval for the company’s first clinical study using robotic-enabled microsurgical techniques to address Alzheimer’s disease. The study, known as REMIND (Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease), marks a milestone in the potential use of precision robotics to explore new therapeutic pathways for neurodegenerative conditions.
The REMIND feasibility trial will evaluate the safety and effectiveness of MMI’s Symani Surgical System in restoring lymphatic drainage through deep cervical lymph nodes (dCLNs) in patients with Alzheimer’s disease and confirmed lymphatic obstruction. The study’s primary endpoint will assess device-related serious adverse events within 30 days of the procedure, with additional measures including biomarkers, imaging outcomes, and cognitive assessments tracked over six months.
Recent research has highlighted the role of the brain’s lymphatic system in clearing harmful proteins such as amyloid beta and tau—key factors in the progression of Alzheimer’s disease. MMI’s robotic approach could enable surgeons to reestablish these drainage pathways with microsurgical precision, potentially improving the removal of neurotoxins from the brain and slowing disease progression.
“This FDA approval is more than a milestone for our company—it’s a signal of what’s possible in science when we bring together the right experts, technology, and research,” said Mark Toland, CEO of MMI. “We’re at the threshold of a new era in microsurgery; one where robotic precision could play a central role in unlocking novel treatment pathways for devastating diseases like Alzheimer’s.”
Performing surgery on the deep cervical lymph nodes requires extreme precision, as the target vessels measure approximately 0.2 millimeters in diameter—thinner than two sheets of paper. MMI’s Symani System enables surgeons to operate at this supermicrosurgical scale with enhanced control and reproducibility, reducing variability in outcomes and expanding access to highly specialized procedures.
“The REMIND study offers the potential to open an entirely new chapter in the treatment of neurodegenerative disease,” said Kate Rumrill, Chief Scientific Officer at MMI. “Bringing robotic precision to more surgeons stands to change patient lives and medicine. This study may pave the way for future research into lymphatic microsurgery as a means to improve the lives of millions affected by Alzheimer’s.”
MMI plans to initiate patient enrollment for REMIND in collaboration with leading research institutions across the U.S. and Europe. The study represents an early but significant step toward validating robotic microsurgery as a viable approach for treating complex neurological and systemic diseases.
